financetom
Business
financetom
/
Business
/
Why Tonix Pharmaceuticals (TNXP) Stock Is Rising
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Tonix Pharmaceuticals (TNXP) Stock Is Rising
Mar 24, 2025 6:41 AM

Tonix Pharmaceuticals Holding Corp ( TNXP ) shares are trading higher by 25.3% to $28.85 during Monday’s session after the company announced that the FDA will not require an Advisory Committee meeting for its New Drug Application for TNX-102 SL, a potential new treatment for fibromyalgia.

What To Know: CEO Seth Lederman expressed confidence in the drug's potential to introduce a new class of fibromyalgia treatments. The company anticipates a possible launch in Q4 2025, pending FDA approval.

TNX-102 SL, a sublingual formulation of cyclobenzaprine HCl, previously received Fast Track designation in 2024, expediting its regulatory review.

Tonix says, with over 10 million U.S. adults affected by fibromyalgia, the approval of TNX-102 SL could mark a significant advancement in addressing this chronic pain disorder. Tonix remains optimistic about the drug's potential to meet the unmet needs of fibromyalgia patients.

Read Also: Oil Rises As US And Russia Begin Talks In Saudi Arabia For Ukraine Ceasefire, Black Sea Deal

How To Buy TNXP Stock

By now you're likely curious about how to participate in the market for Tonix Pharmaceuticals ( TNXP ) – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.

In the case of Tonix Pharmaceuticals ( TNXP ), which is trading at $23.03 as of publishing time, $100 would buy you 4.34 shares of stock.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

According to data from Benzinga Pro, TNXP has a 52-week high of $1,146.01 and a 52-week low of $6.76.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
New Mountain Finance Q3 net investment income dips
New Mountain Finance Q3 net investment income dips
Nov 3, 2025
Overview * New Mountain Finance ( NMFC ) Q3 net investment income per weighted average share at $0.32 * Company's NAV per share decreased to $12.06 * Company doubled stock repurchase plan to $100 mln, enhancing financial flexibility Outlook * Company exploring $500 mln secondary portfolio sale to enhance financial flexibility * Company confident in delivering consistent enhanced yield with...
Alkermes Insider Sold Shares Worth $273,442, According to a Recent SEC Filing
Alkermes Insider Sold Shares Worth $273,442, According to a Recent SEC Filing
Nov 3, 2025
04:47 PM EST, 11/03/2025 (MT Newswires) -- Craig C. Hopkinson, Executive Vice President, R&D, and Chief Medical Officer, on November 03, 2025, sold 9,000 shares in Alkermes ( ALKS ) for $273,442. Following the Form 4 filing with the SEC, Hopkinson has control over a total of 69,740 ordinary shares of the company, with 69,740 shares held directly. SEC Filing:...
Lumine Group Q3 revenue rises on acquisitions
Lumine Group Q3 revenue rises on acquisitions
Nov 3, 2025
Overview * Lumine Group ( LMGIF ) Q3 revenue grows 5% yr/yr, driven by acquisitions * Net income for Q3 rises 36% yr/yr, reflecting improved profitability * Cash flow from operations up 143% yr/yr, driven by lower non-cash working capital Outlook * Lumine Group ( LMGIF ) did not provide specific future guidance Result Drivers * ACQUISITIONS - Revenue growth...
JELD-WEN misses Q3 revenue estimates, net loss widens
JELD-WEN misses Q3 revenue estimates, net loss widens
Nov 3, 2025
Overview * Doors and windows maker JELD-WEN's Q3 2025 revenue fell 13.4%, missing analysts' expectations * Net loss from continuing operations widened due to goodwill impairment and tax items * Company to reduce North American and Corporate workforce by 11% by year-end 2025 Outlook * JELD-WEN ( JELD ) lowers 2025 revenue guidance to $3.1-$3.2 bln, down from $3.2-$3.4 bln...
Copyright 2023-2026 - www.financetom.com All Rights Reserved